Commercialization of E2’s Hēlo Thrombectomy Platform for PE Supported by New Financing

April 7, 2026—Endovascular Engineering, Inc. (E2), a commercial-stage medical technology company focused on the treatment of venous thromboembolism (VTE), announced new financing to support commercialization of its Hēlo thrombectomy platform for the treatment of pulmonary embolism (PE).

According to the company, the Hēlo platform is indicated for the nonsurgical removal of emboli and thrombi from pulmonary arteries and venous vasculature. It is intended for use in the peripheral veins and for the treatment of PE. The system allows for injection, infusion, and/or aspiration of contrast media and other fluids into or from blood vessels.

“This is a pivotal milestone for E2 as we continue our mission to improve options for patients and physicians in the VTE space,” said Dan Rose, Chief Executive Officer at E2. “We are incredibly proud of the capabilities of the Hēlo platform, and this financing enables us to build a strong commercial organization while continuing important investments in R&D and Operations.”

The press release advised that the oversubscribed $80 million Series C financing was led by Gilde Healthcare and Norwest, with participation from existing investors including Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, M&L Healthcare Investments, as well as the two existing undisclosed strategic investors and a new global strategic investor. Geoff Pardo, general partner at Gilde Healthcare, and Zack Scott, MD, general partner at Norwest will join the E2 board.